The federal reclassification of medical cannabis from Schedule I to Schedule III under the Controlled Substances Act has elicited a range of responses from Nebraska federal and state representatives, as the state slowly implements its voter-approved medical cannabis program. This administrative adjustment by the Department of Justice (DOJ) aims to acknowledge state-level medical marijuana regulations and facilitate further research, a development closely watched by industry stakeholders and policy professionals.
Federal Medical Cannabis Rescheduling Details
Acting U.S. Attorney General Todd Blanche announced the immediate downgrade of state-licensed and U.S. Food and Drug Administration-approved marijuana products to Schedule III. Previously, cannabis was classified as a Schedule I drug, alongside substances like heroin and LSD, indicating a high potential for abuse and no currently accepted medical value. Schedule III drugs, such as Tylenol with codeine and ketamine, are defined as having a moderate to low potential for physical and psychological dependence.
According to a report by Marijuana Moment, Blanche stated that this rescheduling action “allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.” The DOJ’s move also recognized the “longstanding regulation of medical marijuana by state governments and the need for a commonsense approach to this reality.” The U.S. Drug Enforcement Administration (DEA) is proceeding with a public comment period, beginning June 29, to formalize the reclassification.
Nebraska Officials’ Reactions to the Federal Shift
Reactions from Nebraska’s political figures have been varied. U.S. Rep. Don Bacon (R-Neb.) expressed support for the reclassification, noting its necessity for research. “Schedule I classification restricts the ability of scientists and doctors to conduct proper research into marijuana in a way that is counterproductive,” Bacon stated, adding his support as long as individual state laws are not preempted.
Conversely, U.S. Sen. Pete Ricketts (R-Neb.) reiterated his long-standing opposition to cannabis, stating, “My stance on this issue has been clear. I remain committed to combatting the growing public health and safety threat marijuana poses.” Ricketts, along with U.S. Rep. Mike Flood (R-Neb.), had previously urged against the reclassification in congressional letters. Nebraska Gov. Jim Pillen (R) and Attorney General Mike Hilgers (R) have also voiced opposition to rescheduling. Governor Pillen affirmed that the federal change “does not alter the ongoing regulatory process to legalize medical marijuana in Nebraska” and that the Nebraska Medical Cannabis Commission would continue its work.
The Nebraska Attorney General’s Office, through spokesperson Suzanne Gage, indicated it is “currently reviewing” the federal changes. Attorney General Hilgers had previously led a coalition of 10 other states in opposing similar rescheduling efforts.
State-Level Implementation and Legal Challenges
In November 2024, Nebraska voters approved the legalization of medical cannabis, establishing the Nebraska Medical Cannabis Commission to oversee the state’s supply chain. While the commission has drafted regulations, no licensed state dispensaries are yet operational. The state’s regulatory framework is currently under review by the Attorney General’s office.
Legal challenges persist at the state level. The Attorney General’s office has previously suggested it could challenge Nebraska’s medical cannabis laws on preemption grounds, arguing federal law supersedes state legalization. A district court case making similar arguments was dismissed last year and is now under appeal to the Nebraska Supreme Court. The implications of the federal medical cannabis rescheduling for these ongoing legal arguments remain to be seen.
Separately, the Omaha Tribe of Nebraska is advancing its own medical cannabis program, seeking partners to provide regulated access to patients. John Cartier, attorney general for the Omaha Tribe, noted that the federal reclassification removes a key “prohibitionist talking point” regarding cannabis’s lack of accepted medical use, potentially bolstering tribal initiatives.
Advocates, such as Crista Eggers of Nebraskans for Medical Marijuana, suggest that any continued delay or obstruction of medical cannabis access by state officials is now a “personal and a political choice,” rather than a necessity dictated by federal classification.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
